John C. Martin, the chief executive officer of Gilead Sciences Inc. , has become a billionaire on the prospects of a powerful new hepatitis C drug that's attracting scrutiny from payers and activists over its $1,000 per pill price tag.
http://ift.tt/1ePlbO0?
http://ift.tt/1ePlbO0?
No comments:
Post a Comment